Sage Mountain Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,108
Closed -$1.8M 539
2025
Q4
$1.8M Sell
3,108
-454
-13% -$257K 0.1% 108
2025
Q3
$1.73M Buy
3,562
+982
+38% +$457K 0.1% 108
2025
Q2
$1.05M Buy
2,580
+153
+6% +$64K 0.07% 135
2025
Q1
$1.21M Buy
2,427
+8
+0.3% +$4.33K 0.09% 98
2024
Q4
$1.26M Buy
2,419
+468
+24% +$257K 0.09% 99
2024
Q3
$1.21M Buy
1,951
+57
+3% +$33.7K 0.1% 97
2024
Q2
$1.05M Buy
1,894
+446
+31% +$256K 0.1% 96
2024
Q1
$842K Buy
1,448
+272
+23% +$153K 0.09% 108
2023
Q4
$624K Sell
1,176
-172
-13% -$83.3K 0.07% 112
2023
Q3
$682K Buy
1,348
+75
+6% +$40K 0.09% 91
2023
Q2
$664K Sell
1,273
-10
-0.8% -$5.4K 0.09% 94
2023
Q1
$739K Buy
1,283
+741
+137% +$418K 0.12% 77
2022
Q4
$298K Buy
542
+64
+13% +$33.9K 0.07% 108
2022
Q3
$242K Buy
478
+61
+15% +$34.1K 0.06% 135
2022
Q2
$227K Buy
417
+66
+19% +$36.3K 0.04% 400
2022
Q1
$207K Sell
351
-199
-36% -$114K 0.03% 455
2021
Q4
$367K Buy
550
+80
+17% +$49.9K 0.04% 393
2021
Q3
$269K Buy
+470
New +$258K 0.04% 380

Other funds holding TMO

Sage Mountain Advisors's TMO Position: Q1 2026 in Review

Sage Mountain Advisors sold out of Thermo Fisher Scientific (TMO) in Q1 2026, closing a stake of 3,108 shares — an estimated $1.8M sold.

Sage Mountain Advisors first reported a position in TMO in Q3 2021 and held it in 18 quarters. The position peaked at $1.8M in Q4 2025. 2,588 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Sage Mountain Advisors reported no remaining Thermo Fisher Scientific position as of Q1 2026 after selling out during the quarter.
  • Sage Mountain Advisors sold 3,108 Thermo Fisher Scientific shares in Q1 2026, an estimated $1.8M.
  • Sage Mountain Advisors first reported a position in Thermo Fisher Scientific in Q3 2021 and held it in 18 quarters.
  • Sage Mountain Advisors's Thermo Fisher Scientific position peaked at $1.8M in Q4 2025.
  • 2,588 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Sage Mountain Advisors's 13F filing for Q1 2026, filed 11 May 2026.